Review ArticleClinical neurorestorative cell therapies: Developmental process, current state and future prospective
Cited by (0)
Hongyun Huang, honorary director and chief expert of Institute of Neurorestoratology, The Third Medical Centre, Chinese PLA General Hospital, China; president of the Beijing Hongtianji Neuroscience Academy, China; founder of the discipline of Neurorestoratology and founding president of the International Association of Neurorestoratology (IANR). He focuses on clinical functional neurorestoration for patients with central nervous diseases and damage through cell based comprehensive neurorestorative therapies; and focuses on the develop- ment of Neurorestoratology.
Lin Chen, director of the Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine China. He focuses on neurorestoration of spinal cord injury, stoke, facial paralysis etc. by cell therapy, neuromodulation and pharmacy; and trigeminal neuralgia and hemifacial spasm by restorative microvascular decompression surgery.
Gengsheng Mao, professor and director of Institute of Neurorestoratology, the Third Medical Centre, Chinese PLA General Hospital, China. He focuses on functional neurorestoration of stroke and Parkinson’s disease through conventional treatment and cell therapy.
Hari Shanker Sharma, director of Int. Exp. CNS Injury & Repair (IECNSIR), professor of Neurobiology (MRC); docent in Neuroanatomy (UU), Anesthesiology & Intensive Care Medicine, the Department of Surgical Sciences, University Hospital, Uppsala University, Sweden; past president of IANR. He focuses on neuroprotection and neuroregeneration in relation to the BBB in stress, trauma, and drugs of abuse in health and diseases using nanotechnology.